Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...